PMID- 29390493
OWN - NLM
STAT- MEDLINE
DCOM- 20180214
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 51
DP  - 2017 Dec
TI  - Traditional Chinese medicine as an adjunctive therapy to oral montelukast for 
      treating patients with chronic asthma.
PG  - e9291
LID - 10.1097/MD.0000000000009291 [doi]
LID - e9291
AB  - BACKGROUND: This study aimed to explore the efficacy and safety of Ping Chuan Ke 
      Li (PCKL) as an adjunctive therapy to oral montelukast compared with placebo plus 
      montelukast for treating patients with chronic asthma (CAS). METHODS: This 
      randomized controlled trial involved 72 patients with CAS. They were randomly 
      allocated to an intervention group or a control group, 36 subjects per group. 
      Participants in the intervention group received PCKL and oral montelukast, while 
      those in the control group received placebo and oral montelukast. The primary 
      outcome was lung function, measured by forced expiratory volume in 1 second 
      (FEV1). The secondary outcomes included quality of life, measured by St. George's 
      Respiratory Questionnaire (SGRQ), and adverse events (AEs). RESULTS: Compared to 
      placebo plus montelukast, PCKL and montelukast revealed greater efficacy in lung 
      function, measured by FEV1 (P <.05), and quality of life, measured by the SGRQ 
      scale (P <.05). Additionally, no significant differences were found in AEs 
      between the 2 groups. CONCLUSION: Traditional Chinese medicine PCKL as an 
      adjunctive therapy to oral montelukast alleviated the symptoms of CAS. Future 
      studies with larger sample sizes are still needed to verify the efficacy and 
      safety of PCKL plus montelukast in patients with CAS.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights 
      reserved.
FAU - Wang, Xuehui
AU  - Wang X
AD  - Department of Respiratory Medicine, First Affiliated Hospital of Heilongjiang 
      University of Chinese Medicine, Harbin, China Department of Graduate, 
      Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Tian, Ziting
AU  - Tian Z
FAU - Gao, Fengli
AU  - Gao F
FAU - Zhang, Xia
AU  - Zhang X
FAU - Liu, Jianqiu
AU  - Liu J
FAU - Li, Zhuying
AU  - Li Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Acetates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - MHM278SD3E (montelukast)
SB  - IM
MH  - Acetates/*therapeutic use
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Asthma/*diagnosis/*therapy
MH  - China
MH  - Cyclopropanes
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Hospitals, University
MH  - Humans
MH  - Male
MH  - Medicine, Chinese Traditional
MH  - Middle Aged
MH  - Quality of Life
MH  - Quinolines/*therapeutic use
MH  - Respiratory Function Tests
MH  - Risk Assessment
MH  - Statistics, Nonparametric
MH  - Sulfides
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC5758195
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/02/03 06:00
MHDA- 2018/02/15 06:00
PMCR- 2017/12/22
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/15 06:00 [medline]
PHST- 2017/12/22 00:00 [pmc-release]
AID - 00005792-201712220-00080 [pii]
AID - MD-D-17-02986 [pii]
AID - 10.1097/MD.0000000000009291 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(51):e9291. doi: 10.1097/MD.0000000000009291.